Lin Zhan
About Lin Zhan
Lin Zhan is the HEOR Lead at BeiGene with extensive experience in oncology-related health economics and outcomes research roles across major pharmaceutical companies.
Current Position at BeiGene
Lin Zhan currently holds the position of HEOR Lead at BeiGene. In this role, he is responsible for leading the Health Economics and Outcomes Research (HEOR) initiatives. His work involves developing strategies to evaluate the economic value and outcomes of oncology treatments, contributing to BeiGene’s mission of improving access to innovative cancer therapies.
Previous Role at Pfizer
From 2018 to 2021, Lin Zhan served as Director of Global Health Economics and Outcomes Research (GHEOR) focusing on oncology at Pfizer. He worked in the Greater New York City Area and was responsible for leading global HEOR projects that supported the value proposition of Pfizer's oncology portfolio.
Experience at Bayer
Lin Zhan worked at Bayer as the Deputy Director of Global Health Economics and Outcomes Research (Oncology) from 2014 to 2018. Based in the Greater New York City Area, Zhan developed HEOR strategies to support Bayer's oncology products, enhancing their market access and demonstrating their economic and clinical value.
Educational Background and Expertise
Lin Zhan holds a Doctoral degree in Pharmacoeconomics/Pharmaceutical Economics from the University of Illinois at Chicago. He also has a Master of Science (MSc) in Health Economics and Outcomes Research from The University of Toledo, and another MSc in Microbiology and Immunology from Shanghai Normal University. His diverse educational background provides a strong foundation for his extensive experience in oncology-related HEOR roles.
International Experience in HEOR
Lin Zhan has significant international experience in the pharmaceutical industry, having worked in both the US and China. He held a leadership position as HEOR Manager (Lead) at Boehringer Ingelheim in Shanghai from 2010 to 2012, before moving to the United States to further his career. This global exposure has enriched his expertise in health economics and outcomes research, particularly in the oncology field.